Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for BARICITINIB
- Efficacy and Safety of Baricitinib in Oral Lichen Planus: a Proof-of-Concept Study
- Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib
- Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
- Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
- Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis
- REVERSE-Long COVID-19 With Baricitinib Pilot Study
- Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia
- Baricitinib in Idiopathic Granulomatous Mastitis
- Inflammation and Depression in People With HIV
- Baricitinib, Methotrexate as Monotherapy or Combination in the Treatment of Rheumatoid Arthritis - an Open Label Randomized Clinical Trial
- Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
- Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- Use of Baricitenib to Maintain of Remission
- Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis
- Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis
- Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
- Baricitinib for Reduction of HIV- CNS
- Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia
- Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis
- Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Treatment of Idiopathic Inflammatory Myopathies
- Baricitinib for Cutaneous Dermatomyositis
- Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
- Stand UP to Rheumatoid Arthritis (SUPRA)
- A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis
- Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19
- Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
- BARIcitinib Cognitive Emotional and Neural signaTuRE
- Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
- Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
- Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus
- Randomized Study of Efficacy of Different Treatment Regimens of Olokizumab
- Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
- COVID-19 VaccinE Response in Rheumatology Patients
- A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)
- Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19
- Efficacy and Safety of Baricitinib in Sjogren's Syndrome
- Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)
- Splenic Stimulation for RA
- Baricitinib in Patients With Relapsing or naïve Dermatomyositis
- Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus
- A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients
- Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
- EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
- Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis
- Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)
- Evaluation of Effect and Tolerance of the Association of Baricitinib and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo
- Baricitinib in New-onset Type 1 Diabetes
- Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
- A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
- A Study of Baricitinib (LY3009104) in Participants With COVID-19
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
- Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial
- Baricitinib Compared to Standard Therapy in Patients With COVID-19
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
- Randomised Evaluation of COVID-19 Therapy
- Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
- Baricitinib Therapy in COVID-19
- Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19
- Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
- Safety and Efficacy of Baricitinib for COVID-19
- Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
- A Phase IIa Trial of the Oral JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
- Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
- A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
- A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
- A Study of Baricitinib in Participants With Rheumatoid Arthritis
- BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica
- A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
- Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
- JAK Inhibitor Treatment in AGS
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
- A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
- A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
- A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- Examination of Efficacy and Safety of Baricitinib in RA Patients
- A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA
- A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis
- Effect of Baricitinib Treatment on Peripheral Bone in RA
- A Study of Baricitinib in Participants With Systemic Lupus Erythematosus
- A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus
- A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
- A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
- A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
- A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisa
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
- Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
- A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
- A Study of Baricitinib in Healthy Participants
- Baricitinib in Relapsing Giant Cell Arteritis
- Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
- A Study of Baricitinib (LY3009104) in Healthy Chinese Participants
- A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
- A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis
- A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)
- A Study of Baricitinib in Healthy Japanese Participants
- A Study of Baricitinib and Ciclosporin in Healthy Participants
- A Study of Baricitinib and Simvastatin in Healthy Participants
- A Study of Baricitinib and Probenecid in Healthy Participants
- A Study of Baricitinib and Omeprazole in Healthy Participants
- A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants
- A Study of Baricitinib and Rifampicin in Healthy Participants
- A Study of Baricitinib and Birth Control Pills in Healthy Females
- An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis
- A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
- A Study in Moderate to Severe Rheumatoid Arthritis Participants
- A Moderate to Severe Rheumatoid Arthritis Study
- A Study in Participants With Moderate to Severe Rheumatoid Arthritis
- A Study in Moderate to Severe Rheumatoid Arthritis
- A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
- A Study of LY3009104 in Healthy Participants
- A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
- Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy
- Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects
- A Study of LY3009104(Baricitinib) for Healthy Subjects
- A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy
- INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
Clinical trials list
click for details